Eric Miller

GI Radiation Oncologist at Ohio State University Comprehensive Cancer Center

[Alliance for Clinical Trials in Oncology @ALLIANCE_org]

🚨 Milestone reached: The ERASur colorectal cancer trial has surpassed one third patient accrual nationwide. The study is evaluating whether aggressive local therapy can improve survival in limited metastatic disease. #ClinicalTrials #ColorectalCancer https://t.co/oDCwtkEUxF

[Alliance for Clinical Trials in Oncology @ALLIANCE_org]

The #ERASur trial is enrolling patients with #colorectalcancer that has spread beyond the liver. Patients who responded to initial chemo & have up to 4 treatable cancer sites are eligible to participate. Learn more: https://t.co/TilD1BI5zg #ColorectalCancerAwarenessMonth

[Alliance for Clinical Trials in Oncology @ALLIANCE_org]

#DYK #ERASur led by @EricMillerMDPhD @OSUCCC_James is testing whether adding targeted treatments like surgery, radiation or heat therapy to standard chemo can help people w/metastatic #colorectalcancer live longer: https://t.co/TilD1BI5zg @FightCRC @ColorectalCAN @ColonCancerCoal

[ECOG-ACRIN Cancer Research Group @eaonc]

#ClinicalTrial EA2222/PUMP, led by @michael_lidsky, is a randomized phase 3 study of #SystemicTherapy with or without hepatic arterial infusion for unresectable #Colorectal liver metastases. More here: https://t.co/xBChV6GALe cc: @MichaelDAngeli2, @skmaithel, @AndreaCercek

[Fight Colorectal Cancer @FightCRC]

What if Stage IV colorectal cancer could be treated with curative intent? The ERASur trial is testing total ablative therapy—surgery, radiation, and ablation—for people with oligometastatic disease. This could be a game-changer. 💙 #ASCO25 #ERASur

🔗: https://t.co/LKjREJ7O0a

[Eric Miller @EricMillerMDPhD]

@sepideh_gholami with a master class on the role of HAIP for patients with liver-confined mCRC and the need for modern prospective data for this patient group with the EA2222 PUMP trial led by @michael_lidsky @ASCO @colontown @FightCRC @eaonc

[Eric Miller @EricMillerMDPhD]

The @AshishManne trifecta @ASCO
@OSUCCC_James

[Leila Tchelebi @LeilaTchelebi]

Out today! @AnkerUVMRadOnc and I chat with @SalmaJabbour1 about our @RadiumSociety non-op guidelines for #RectalCancer on today's @IJROBP podcast! Shout-out to co-authors @KrishanJethwa @PercyLeeMD @VonettaMW @WilliamSmallJr and the rest of the team!
https://t.co/MVWRJJRDQj

[Alliance for Clinical Trials in Oncology @ALLIANCE_org]

For #TrialTuesday, .@EricMillerMDPhD @OSUCCC_James leads @ALLIANCE_org A022101/ERASur, a metastatic #colorectalcancer trial that compares total ablative therapy & usual systemic therapy to usual systemic therapy alone: https://t.co/TilD1BI5zg #NCI #NCTN .@FightCRC .@CCAlliance

[Michael Chuong @MikeChuongMD]

This month's @IJROBP Oncology Scan features commentary on several impactful GI trials by @EricMillerMDPhD @NiuSanford @adapthyun @KrishanJethwa @andrzejw Jon Ashman Maria Hawkins
☑️ESOPEC
☑️RTOG 1112
☑️ABC-07
☑️CROSSFIRE
☑️RTOG 0848

https://t.co/cWfs4wjYTU

[Lauren Henke, MD, MSCI @lauren_henke]

Great to be in San Antonio representing the RO team and highlighting the growing data for SBRT/hypofrac RT 💥for HCC, Cholangio, and metastatic liver disease with @EricMillerMDPhD @nbn426 and @eugenekoay at #SALCS 💫 thanks for the invite!! @RadOncUH @MDAndersonNews @OhioStateRadOnc

[Neil Newman @nbn426]

#SALCS 2024 tumor board on challenging HCC cases. @lauren_henke is crushing it explaining not only the data for SBRT but also the vast array of tools we have at our disposal (cbct, lipodol, fiducials, adaptive , motion management, beam control ) to ensure safe and highly effective doses to definitively treat HCC.

[Eric Miller @EricMillerMDPhD]

@smitha42 @CathyEngMD @jonathanloree @NCICTEP_ClinRes Congratulations @smitha42!!! Well-deserved!!

[Eric Miller @EricMillerMDPhD]

@AnkerUVMRadOnc @UVMcancercenter I can’t think of anyone more deserving!

[#CRCTrialsChat @CrcTrialsChat]

Adding this #ERASur study update from the @colontown #DocTalk by Dr @EricMillerMDPhD today on SBRT organized by @BetsyPost2

[Betsy Post @BetsyPost2]

📌 Save the Date for our next DocTalk 👨‍⚕️— July 10th at 7pm EDT on Zoom — I am thrilled to host @EricMillerMDPhD to discuss #SBRT for #CRC Liver and Lung Mets. (We will also discuss the ERASur trial.) Our patients in @colontown can’t wait for this one! 💙 #crcsm

[Eric Miller @EricMillerMDPhD]

So excited to see ERASur open @VUMC_Cancer and to work with @CathyEngMD and her team on this important study!
@colontown @hitchcock_kate @DrPaulRomesser @sepideh_gholami

[Dr. Cathy Eng @CathyEngMD]

Activated today @VUMC_Cancer the Phase III @NCICTEP_ClinRes ERASur study for stage 4: #colorectalcancer #cancer #cancerresearch
🔷 1st line chemo >/= 4M
🔷chemo +/- ablation
🔷 </=4 sites of mets
⭐️ PI @EricMillerMDPhD @OSUCCC_James @ALLIANCE_org

https://t.co/ibjpa58LKU

[Eric Miller @EricMillerMDPhD]

Outstanding job by @KarynAGoodman putting ESOPEC into context!

[Jun Gong, MD @jgong15]

@KarynAGoodman @TischCancer plenary discussant of ESOPEC trial

FLOT vs CROSS story settled but ?’s:
Lower CROSS completion, pCR rate (timing of surgery 4-6 wks in ESOPEC vs 6-8 wks of CROSS?), OS & no adj nivo in control

Can we combine both as next step?

#ASCO24 @OncoAlert

[Pashtoon Kasi MD, MS @pashtoonkasi]

#ASCO24 @ASCO

Interesting to see that additional use of local therapies to chase “oligo” metastases in more extensive metastatic #colorectalcancer didn’t add much to survival.

🔌 for ongoing @ALLIANCE_org ERASUR study. “Multi-organ” definitions are very different.

@OncoAlert

[Eric Miller @EricMillerMDPhD]

An important study, but about 1/3 of patients with peritoneal disease. We need more prospective data to better counsel our patients, including completion of #ERASur

https://t.co/ilgppc3L76

@hitchcock_kate @DrPaulRomesser @sepideh_gholami @colontown

[Jun Gong, MD @jgong15]

Eligibility and patient characteristics for PhIII ORCHESTRA trial

#ASCO24 @OncoAlert @OncologyTimes